What to Expect at the 4th Novel Conjugates Summit
The 4th Novel Conjugates Summit is the only event offering comprehensive insights into the latest innovations in conjugated drugs. From antibody-degrader conjugates to bispecific ADCs and peptide drug conjugates, join us to take a data-driven dive into each of their value propositions and learn how they can tackle challenges that traditional ADCs have faced by overcoming resistance mechanisms, reducing off target toxicity, improving tumor penetration as well as targeting new indications.
Connect with 100+ experts from big pharma, cutting-edge biotechs and conjugation and manufacturing providers, all sharing crucial insights on striking success with new formats and payloads.
Now is the time to expand your conjugate design toolkit to pursue emerging cancer targets and stay ahead in the race to deliver safer, more targeted therapies beyond traditional ADCs Join us to explore the most promising new targeting vectors and payloads that are set to revolutionize the landscape of conjugated drugs in 2025!
Top 5 Takeaways:
1
2
3
4
5
Explore how Pfizer, Eisai, Orum Therapeutics, and Nurix are pioneering the future of antibody-degrader conjugates by exploring their strategies for choosing the right targets, optimizing linkers, and advancing these innovative molecules into the clinic.
Leverage bispecific ADCs by understanding the essential design considerations for bispecific antibodies, while delving into target selection with insights from BiVictriX, Valink Therapeutics, Salubris Biotherapeutics, and more.
Learn how companies like ProteinQure, A28 Therapeutics, and Bicycle Therapeutics are using peptide-drug conjugates to enhance intracellular delivery and cross the blood-brain barrier.
Explore the broadening applications of novel bioconjugates beyond oncology. Hear from Dyne Therapeutics and Entrada about overcoming chemistry and conjugation challenges to bring these therapies into the clinic.
Take a deep dive into how different targeting moieties and payloads can alter the PK/PD profiles of bioconjugate drugs and consider how these factors can be strategically managed to enhance therapeutic outcomes.
Who Will You Meet?
Join 100+ attendees from innovation and business development all looking for the next hottest conjugate approach to take ADCs to the next level.
Previous Attending Companies Include:
